In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC

References

• Wang P, She G, Yang Y, et al. Synthesis and biological evaluation of new ligustrazine derivatives as antitumor agents. Molecules 2012;17:4972–85
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Y, Xu K, et al. A new ligustrazine derivative. pharmacokinetic evaluation and antitumor activity by suppression of NF-κB/p65 and COX-2 expression in S180 mice. Pharmazie 2013;68:1–8
   Google Scholar
• Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964--1985). Br J Clin Pharmacol 1988;25:387–96
   PubMed Web of Science ®Google Scholar
• Hou P, Ni J, Cao S, et al. Preparation and evaluation of solid dispersions of a new antitumor compound based on early-stage preparation discovery concept. AAPS PharmSciTech 2013;14:629–38
   PubMed Web of Science ®Google Scholar
• Shishu, Kamalpreet, Maheshwari M. Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model. Drug Dev Ind Pharm 2012;38:294–300
   PubMed Web of Science ®Google Scholar
• Patel ZB, Patel KS, Shah AS, Surti NI. Preparation and optimization of microemulsion of rosuvastatin calcium. J Pharm Bioallied Sci 2012;4:S118–19
   PubMedGoogle Scholar
• Nair R, Chakrapani M, Kaza R. Preparation and evaluation of vancomycin microemulsion for ocular drug delivery. Drug Deliv Lett 2012;2:26–34
   Google Scholar
• Tandel H, Raval K, Nayani A, Upadhay M. Preparation and evaluation of cilnidipine microemulsion. J Pharm Bioallied Sci 2012;4:S114–15
   PubMedGoogle Scholar
• Inactive ingredient search for approved drug products. FDA/Center for Drug Evaluation and Research. 2012. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm [last accessed 19 Sep 2012]
   Google Scholar
• Scott Swenson E, Curatolo WJ. Means to enhance penetration: (2) intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev 1992;8:39–92
   Web of Science ®Google Scholar
• Li-Li C, Ying-Jie D, Yong Z, Wen-Wen M. Formulation and characterization of water-in-oil microemulsions for oral delivery of thymopentin. J Shengyang Pharm Univ 2010;8:599–604
   Google Scholar
• Yin Y-M, Cui F-D, Mu C-F, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009;140:86–94
   PubMed Web of Science ®Google Scholar
• Du H, Feng Q, Yang X, et al. “Whole Chinese angelica” microemulsion: its preparation and in vivo and in vitro evaluations. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi: 10.3109/03639045.2013.819881
   Web of Science ®Google Scholar
• Shao B, Tang J, Ji H, et al. Enhanced oral bioavailability of Wurenchun (Fructus Schisandrae Chinensis extracts) by self-emulsifying drug delivery systems. Drug Dev Ind Pharm 2010;36:1356–63
   PubMed Web of Science ®Google Scholar
• Ryu JK, Yoo SD. Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability. Drug Dev Ind Pharm 2012;38:1313–18
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Arafa MF, Osman MA. Microemulsion for simultaneous transdermal delivery of benzocaine and indomethacin: in vitro and in vivo evaluation. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi: 10.3109/03639045.2013.841186
   PubMed Web of Science ®Google Scholar
• Sarciaux JM, Acar L, Sado PA. Using Microemulsion formulations for oral drug delivery of therapeutic peptides. Int J Pharm 1995;120:127–36
   Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs prescription design. J Control Release 2002;81:65–74
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Hayashi T, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs: II. In vivo study. J Control Release 2002;81:75–82
   PubMed Web of Science ®Google Scholar
• Araya H, Tomita M, Hayashi M. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int J Pharm 2005;305:61–74
   PubMed Web of Science ®Google Scholar
• Tenjaria S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 1999;16:461–521
   PubMed Web of Science ®Google Scholar
• Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15–23
   Web of Science ®Google Scholar
• Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995;12:1561–72
   PubMed Web of Science ®Google Scholar
• Sarciaux JM, Acar L, Sado PA. Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int J Pharm 1995;120:127–36
   Web of Science ®Google Scholar
• Silva AC, Kumar A, Wild W, et al. Long-term stability; biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Nanomed 2012;436:798–805
   Google Scholar
• Mohd. Abul Kalam, Sultana Y, Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010;18:191–204
   PubMed Web of Science ®Google Scholar
• Shi F, Zhao J-H, Liu Y, et al. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomed 2012;7:2033–43
   PubMed Web of Science ®Google Scholar
• Chu KR, Lee E, Jeong SH, Park E-S. Effect of particle size on the dissolution behaviors of poorly water-soluble drugs. Arch Pharmacol Res 2012;35:1187–95
   PubMed Web of Science ®Google Scholar
• Zarie ES, Kaidas V, Gedamu D, et al. Solvent free fabrication of micro and nanostructured drug coatings by thermal evaporation for controlled release and increased effects. PLoS One 2012;7:e40746
   PubMedGoogle Scholar
• Spuch C, Hindawi CN. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv 2011. [Epub ahead of print]. doi:10.1155/2011/469679
   Google Scholar
• Qu C, Ni J, Yang I, et al. Altered plasma and brain disposition of isopropylidene shikimic acid liposome in rats and the brain protection in cerebral ischemia–reperfusion. Drug Dev Ind Pharm 2013;39:1291--5
   PubMed Web of Science ®Google Scholar
• Murata M, Yonamine T, Tanaka S, et al. Surface modification of liposomes using polymer–wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration. J Pharm Sci 2013. [Epub ahead of print].| doi:10.1002/jps.23463
   PubMed Web of Science ®Google Scholar
• Liang X-J, Chen C, Zhao Y, et al. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Metab 2008;9:697–709
   PubMed Web of Science ®Google Scholar